Cholangiocarcinoma
Complications of Cirrhosis: Evaluation and Management, Page: 219-227
2015
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Cholangiocarcinoma (CCA), an uncommon biliary adenocarcinoma, can be divided into intrahepatic and extrahepatic types. Intrahepatic CCA (IH-CCA) comprises approximately 25 % of all CCAs, and can be characterized as peripheral mass-forming or central periductal infiltrating tumors. Most patients do not possess known risk factors, but a strong association with cirrhosis has been documented. The clinical presentation of IH-CCA can be nonspecific even in the late stages of the disease. Management combines surgical resection, systemic chemotherapy, and targeted radiation therapy. Surgically unresectable disease is incurable with current treatment options. Enrollment in clinical trials and referral to tertiary centers are recommended for patients with unresectable or recurrent disease.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84944602722&origin=inward; http://dx.doi.org/10.1007/978-3-319-13614-1_23; https://link.springer.com/10.1007/978-3-319-13614-1_23; https://dx.doi.org/10.1007/978-3-319-13614-1_23; https://link.springer.com/chapter/10.1007/978-3-319-13614-1_23
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know